Document is current
Any future updates will be listed below
-
Authors
Azar, Fadi
Deforges, Jules
Demeusoit, Christelle
Kleinpeter, Patricia
Remy, Christelle
Silvestre, Nathalie
Foloppe, Johann
Fend, Laetitia
Spring-Giusti, Clémentine
Quéméneur, Eric
Marchand, Jean-Baptiste https://orcid.org/0009-0007-4151-1754
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05788926 at ClinicalTrials.govnct05788926 at ClinicalTrials.govDocuments that mention this clinical trial
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
https://doi.org/10.1136/jitc-2024-009302
Documents that mention this clinical trial
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
https://doi.org/10.1136/jitc-2024-009302
-
Funding
Funding for this research was provided by:
Transgene SA funded all the work presented in this publication.
- License Information
